Johnson & Johnson's Orthopedics President Departs Amid DePuy Synthes Spin-off and IPO Filing

01

Johnson & JohnsonPresident of DePuy SynthesResignation

Local Time11Month26Day,President of DePuy Synthes, Johnson & Johnson Medical Technology Company, U.S. Orthopaedics DivisionLeslie StormsInLinkedInSaid, sheWill leave this month。Before this, she had already worked at Johnson & Johnson for18Year.

LinkedInData shows，StormsThe career began at Johnson & Johnson,Previously served asNoramcoActive Pharmaceutical Ingredient (API) Global Vice President of Sales and Marketing for the division, which was established in2016Year of sale.2013In that year, she joined the Janssen division of Johnson & Johnson.CNS, Senior Marketing Director.

Thereafter, StormsJoined Johnson & JohnsonVision, held multiple vice president positions over three years, then moved to Johnson & Johnson's medical technology department，FormerlyVice President of Surgical Sales、President of Surgical Sales,And on2023Appointed as President of DePuy Synthes in [Year].

StormsWrote: "I am very fortunate to work with outstanding leaders and a talented team who are passionate about what they do. I am lucky to work for a company that helps me grow.PromptI think differently, encouraging me to bring professional expertise and a fresh perspective, and supporting me and my family at every turn.”

Just last month，Johnson & JohnsonCompanyProposed,Plans to spin off its orthopedics business to enhance the strategic and operational focus of each company; the spin-off is expected to occur in18To24Within months.

After the spin-off is completed,DePuy SynthesWill serve as aIndependent Orthopedic CompanyOperation.Namal NawanaAppointed asDePuy SynthesGlobal President.Previously,He has served asAlere, Smith & Nephew'sCEO，AndHas worked at Johnson & Johnson for over15Year,2011Year served as Johnson & JohnsonDePuy SynthesGlobal President of the Spine Business.

Compared to other relatively younger high-growth tracks, the orthopedic market is already relatively mature. In the third quarter of this year,Johnson & Johnson Medical Global Sales84Billion USD, Year-over-Year Growth6.8%, Operationally year-over-year growth5.6%。The growth is mainly driven by electrophysiology products and the cardiovascular field.AbiomedAndShockwave, Wound healing products in the general surgery field and surgical vision drivers, excluding orthopedic business.

02

Medical Device Giants Collectively Strategize for Lean Operations

Competing for High-Growth, High-Profit Tracks

The spin-off of the orthopedics business is Johnson & JohnsonAccelerateItsTransformation of Medical Technology Business Portfolio Towards High-Growth, High-Profit MarketsAn important measure.In the future, this pharmaceutical giant will become moreFocus on areas in the field of innovative pharmaceuticals and medical technology where needs are not adequately met.

In fact, earlyIn2023Year,Johnson & JohnsonCompanyAs forLaunchedMedTechDepartment of Orthopedics Restructuring Plan: Simplify operations by exiting certain markets, product lines, and distribution networks.

Nowadays, this orthopedic revolution continues to deepen.

Chairman and Chief Executive Officer of Johnson & JohnsonJoaquin DuatoPreviouslyIndicates:“This transaction enables Johnson & Johnson toFurther Strengthen Focus and Investment in High-Growth Areas, thereby effectively extending and improving the lives of patients. The planned split reflects our long-standing commitment to optimizing our portfolio and creating value. We believe,As an independent business, our orthopedics business will be better positioned to drive revenue growth and operating margin expansion.”

Johnson & Johnson's split is not an isolated case. Currently, a wave of breakups is sweeping through the medical device industry.

5Month,MedtronicAnnouncementPlans to spin off its diabetes business.Currently,Medtronic is taking decisive and ongoing portfolio management and capital allocation actions, shifting more focus to the highest-profit growth drivers related to its core strengths. The company is building its growth momentum, advancing its innovation pipeline and“Instant”Product Release, IncludingPulse Field Ablation, Renal Denervation, Implantable Tibial Nerve Modulation, and Soft Tissue Robotics。

2Month，TeleflexAnnounced the split into two listed companies, and its urology, emergency care andOEMThe business will be spun off into a new publicly listed company, while the remaining vascular access, interventional, and surgical businesses..., focusing on high-growth, highly sensitive emerging end markets primarily centered around hospitals.

BDHealthcareThis year2MonthAnnouncement of the Split of Bioscience Business and Diagnostic Solutions Business7MonthAgainAnnouncement, willThrough Value175Billion-dollar dealSell this part of the business。Next,BDThe focus of healthcare will be onMedical Device Department（Drug Delivery Solutions, Drug Management Solutions, Pharmaceutical Systems, Advanced Patient Monitoring）AndInterventional Department（Surgery, Peripheral Intervention, Urology, and Intensive Care）。

Behind the "Spin-off Wave" is a Strategic Focus. The pursuit of innovation and high-growth areas has become a consensus among global device giants, and proactively doing "subtraction" has also become a common choice for these enterprises.

The competitive logic in the medical technology industry is quietly shifting, from pursuing comprehensive confrontations between giants to a competition focused on swift and specialized innovation value. The efficiency revolution driven by innovation is reshaping the competitive landscape of the global medical device market.

END